Northeast Pharmaceutical Group Co., Ltd. specializes in the production and marketing of pharmaceutical ingredients and preparations. The group's products include antibiotics, vitamins, cardiovascular treatments, anesthetics, medical plants, etc. China accounts for 86.3% of net sales.

Employees

5,727

Sector

Pharmaceuticals

Calendar

25/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	CN¥5.030	+1.21%	2,62,94,714
13/26/13	CN¥4.970	+1.22%	3,61,64,406
12/26/12	CN¥4.910	+1.66%	1,86,97,009
11/26/11	CN¥4.830	+0.84%	1,69,77,041
10/26/10	CN¥4.790	+1.05%	1,50,76,093

End-of-day quote Shenzhen S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. 14/08/2026			5-day change	1st Jan Change
5.030 ^CNY	+1.21%		+6.12%	-3.64%

16/06	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
27/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	717.83Cr 106.43Cr 92Cr 86Cr 79Cr 147.69Cr 10TCr 150.13Cr 1.01TCr 395.73Cr 5.1TCr 399.59Cr 390.92Cr 17TCr	P/E 2024	18.2x	P/E 2025	29x
Enterprise Value	568.77Cr 84Cr 73Cr 68Cr 62Cr 117.03Cr 8.06TCr 118.96Cr 801.96Cr 313.56Cr 4.04TCr 316.62Cr 309.74Cr 13TCr	EV / Sales 2024	0.62x	EV / Sales 2025	0.84x
Free-Float	39.51%	Yield 2024	1.9%	Yield 2025	1.05%

16/06	Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for 2025, Payable on 23 June 2026	CI
27/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03/04	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/04	Northeast Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 23, 2026	CI
28/25/28	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
09/25/09	Northeast Pharmaceutical Unit Gets Clinical Trial Approval for Glioma Treatment	MT
08/25/08	Northeast Pharmaceutical Appoints CFO	MT
02/25/02	Northeast Pharmaceutical CFO Resigns	MT
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
05/25/05	Northeast Pharmaceutical Gets Nod to Market Antiobiotic in Europe	MT
28/25/28	Northeast Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Announces Directorate Appointments	CI
26/25/26	Northeast Pharmaceutical Group Co., Ltd. Approves Cash Dividend on (A Shares) for 2024, Payable on 23 June 2025	CI

1 day	+1.21%
1 week	+6.12%
Current month	+9.83%
1 month	+2.65%
3 months	+3.07%
6 months	-1.95%
Current year	-3.64%

Northeast Pharmaceutical Group Co., Ltd. Share Price

Stocks

000597

CNE0000009G0

Pharmaceuticals

Valuation: Northeast Pharmaceutical Group Co., Ltd.

Chart: Northeast Pharmaceutical Group Co., Ltd.

Latest news : Northeast Pharmaceutical Group Co., Ltd.

Press Releases: Northeast Pharmaceutical Group Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Northeast Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4.75	5.13
1 month	4.47	5.13
Current year	4.09	5.73
1 year	4.09	5.98
3 years	3.72	6.69
5 years	3.72	9.3
10 years	3.72	9.3

Manager	Title	Age	Since
Yong Gang Cai CEO	Chief Executive Officer	46	21/01/2025
Xin Li DFI	Director of Finance/CFO	46	06/09/2025
Dong Sheng Yan IRC	Investor Relations Contact	42	01/07/2024

Director	Title	Age	Since
Kai Zhou CHM	Chairman	62	21/01/2025
Xin Hua Ao BRD	Director/Board Member	62	18/07/2018
Cheng Ren Huang BRD	Director/Board Member	62	18/07/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/22	Zhengwei	Buy		36,000	0.0027%
26/05/22	Yan Liu	Buy	Executive/Senior Manager	100	0.0000%
25/05/22	Zhengwei	Buy		28,100	0.0021%

	2024	2025
Net sales	750.26Cr 111.24Cr 96Cr 90Cr 82Cr 154.37Cr 11TCr 156.91Cr 1.06TCr 413.6Cr 5.33TCr 417.64Cr 408.58Cr 18TCr	707.49Cr 104.9Cr 91Cr 85Cr 77Cr 145.57Cr 10TCr 147.97Cr 997.54Cr 390.03Cr 5.02TCr 393.83Cr 385.29Cr 17TCr
Net income	41Cr 6.08Cr 5.25Cr 4.93Cr 4.49Cr 8.43Cr 581.07Cr 8.57Cr 58Cr 23Cr 290.98Cr 23Cr 22Cr 966.97Cr	26Cr 3.86Cr 3.33Cr 3.13Cr 2.85Cr 5.35Cr 368.72Cr 5.44Cr 37Cr 14Cr 184.64Cr 14Cr 14Cr 613.59Cr
Net Debt	-287.58Cr -43Cr -37Cr -35Cr -31Cr -59Cr -4.08TCr -60Cr -405.48Cr -158.54Cr -2.04TCr -160.08Cr -156.61Cr -6.78TCr	-149.05Cr -22Cr -19Cr -18Cr -16Cr -31Cr -2.11TCr -31Cr -210.16Cr -82Cr -1.06TCr -83Cr -81Cr -3.52TCr

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHEAST PHARMACEUTICAL GROUP CO., LTD.	+1.21%	+6.12%	-14.02%	-8.04%	106.43Cr
ELI LILLY AND COMPANY	-2.25%	-0.47%	+68.30%	+116.05%	1,05200Cr
JOHNSON & JOHNSON	-0.66%	+0.43%	+47.39%	+51.02%	63TCr
ABBVIE INC.	-0.54%	+1.39%	+20.69%	+64.61%	44TCr
ROCHE HOLDING AG	-1.99%	-3.32%	+38.71%	+36.26%	35TCr
NOVARTIS AG	-1.05%	-2.81%	+23.07%	+35.91%	29TCr
ASTRAZENECA PLC	-2.12%	-3.67%	-1.14%	+5.35%	24TCr
AMGEN INC.	-0.63%	+1.04%	+40.05%	+56.67%	22TCr
NOVO NORDISK A/S	-1.19%	-3.41%	-9.57%	-53.50%	20TCr
GILEAD SCIENCES, INC.	+0.16%	+3.87%	+16.89%	+77.38%	17TCr
Average	-0.91%	+0.74%	+23.04%	+38.17%	35.96TCr
Weighted average by Cap.	-1.36%	+0.05%	+39.07%	+61.74%